These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 6895487)

  • 1. The prediction of relapse after drug treatment of Graves' disease by assay of long acting thyroid stimulator-protector (LATS-P).
    Hardisty CA; Hanford L; Munro DS
    Clin Endocrinol (Oxf); 1981 May; 14(5):509-17. PubMed ID: 6895487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of radioiodine and antithyroid drugs on serum long acting thyroid stimulator protector (IATS-P). A three year prospective study.
    Hardisty CA; Fowles A; Munro DS
    Clin Endocrinol (Oxf); 1984 May; 20(5):597-605. PubMed ID: 6547647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-acting thyroid stimulator (LATS) and long acting thyroid stimulator protector (LATS-P) in untreated thyrotoxicosis.
    Hardisty CA; Hanford L; Humphries H; Munro DS
    Clin Endocrinol (Oxf); 1981 Jun; 14(6):631-9. PubMed ID: 6895353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thyrotrophin binding inhibiting immunoglobulins in Graves' disease before, during and after antithyroid therapy, and its relation to long-acting thyroid stimulator.
    Docter R; Bos G; Visser TJ; Hennemann G
    Clin Endocrinol (Oxf); 1980 Feb; 12(2):143-53. PubMed ID: 6105023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum long acting thyroid stimulator (LATS) and LATS-protector (LATS-P) in Graves' disease associated with localized myxedema.
    Hardisty CA; Fowles A; Munro DS
    J Endocrinol Invest; 1984 Apr; 7(2):151-5. PubMed ID: 6547156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum long acting thyroid stimulator protector in pregnancy complicated by Graves' disease.
    Hardisty CA; Munro DS
    Br Med J (Clin Res Ed); 1983 Mar; 286(6369):934-5. PubMed ID: 6403139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissociation of serum LATS activity and hyperfunction and autonomy of the thyroid gland in Graves' disease.
    Hennemann G; Dolman A; Docter R; De Reus A; Van Zijl J
    J Clin Endocrinol Metab; 1975 Jun; 40(6):935-41. PubMed ID: 1173367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimum duration of antithyroid drug treatment determined by assay of thyroid stimulating antibody in patients with Graves' disease.
    Edan G; Massart C; Hody B; Poirier JY; Lé Reun M; Hespel JP; Leclech G; Simon M
    BMJ; 1989 Feb; 298(6670):359-61. PubMed ID: 2564286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection and properties of TSH-binding inhibitor immunoglobulins in patients with Graves' disease and Hashimoto's thyroiditis.
    Endo K; Kasagi K; Konishi J; Ikekubo K; Okuno T; Takeda Y; Mori T; Torizuka K
    J Clin Endocrinol Metab; 1978 May; 46(5):734-9. PubMed ID: 45421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of partial thyroidectomy for Graves' disease on serum long-acting thyroid stimulator protector (LATS-P).
    Hardisty CA; Talbot CH; Munro DS
    Clin Endocrinol (Oxf); 1981 Feb; 14(2):181-8. PubMed ID: 6894891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The assay of Graves' immunoglobulins: a comparison of different methods.
    Hardisty CA; Kendall-Taylor P; Atkinson S; Humphries H; Munro DS
    Clin Endocrinol (Oxf); 1983 Jun; 18(6):637-44. PubMed ID: 6136348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of outcome in Graves' disease after carbimazole treatment.
    Weetman AP; Ratanachaiyavong S; Middleton GW; Love W; John R; Owen GM; Darke C; Lazarus JH; Hall R; McGregor AM
    Q J Med; 1986 Apr; 59(228):409-19. PubMed ID: 2875484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.
    Maugendre D; Massart C
    Clin Endocrinol (Oxf); 2001 Jan; 54(1):89-96. PubMed ID: 11167931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of remission after antithyroid drug treatment in Graves' disease.
    Young ET; Steel NR; Taylor JJ; Stephenson AM; Stratton A; Holcombe M; Kendall-Taylor P
    Q J Med; 1988 Feb; 66(250):175-89. PubMed ID: 2902655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Graves' disease: thyroid function and immunologic activity.
    Gossage AA; Crawley JC; Copping S; Hinge D; Himsworth RL
    J Nucl Med; 1982 Nov; 23(11):973-7. PubMed ID: 6290623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-acting thyroid stimulator and related factors.
    Kendall-Taylor P; Dirmikis SM; Munro DS
    Proc R Soc Med; 1975 Apr; 68(4):252-3. PubMed ID: 1242809
    [No Abstract]   [Full Text] [Related]  

  • 17. The prognostic value of parallel measurements of thyrotropin binding inhibiting immunoglobulins (TBII) and thyroid adenylate cyclase stimulating antibodies (TSAb) in Graves' disease after longterm antithyroid treatment.
    Bliddal H; Bech K; Siersbaek-Nielsen K; Friis T
    J Endocrinol Invest; 1983 Aug; 6(4):259-62. PubMed ID: 6139399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of LATS activity and TSH receptor antibody in Graves' disease.
    Kajita Y; Nakajima Y; Ishida M; Ura Y; Ochi Y; Miyazaki T; Hachiya T; Ijichi H
    Endocrinol Jpn; 1984 Jun; 31(3):369-74. PubMed ID: 6094169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Propylthiouracil and carbimazole associated-antineutrophil cytoplasmic antibodies (ANCA) in patients with Graves' disease.
    Harper L; Chin L; Daykin J; Allahabadia A; Heward J; Gough SC; Savage CO; Franklyn JA
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):671-5. PubMed ID: 15163328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific and nonspecific responses in the bioassay of long-acting thyroid stimulator (LATS).
    Chopra IJ; Solomon DH; Limberg NP
    J Clin Endocrinol Metab; 1970 Oct; 31(4):382-90. PubMed ID: 5468701
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.